Literature DB >> 17881206

Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes).

R W Dal Negro1, S Tognella, R Tosatto, M Dionisi, P Turco, C F Donner.   

Abstract

Chronic respiratory diseases affect a large number of subjects in Italy and are characterized by high socio-health costs. The aim of the Social Impact of Respiratory Integrated Outcomes (SIRIO) study was to measure the health resources consumption and costs generated in 1 year by a population of patients with chronic obstructive pulmonary disease (COPD) in a real-life setting. This bottom-up, observational, prospective, multicentric study was based on the collection of demographic, clinical, diagnostic, therapeutic and outcome data from COPD patients who reported spontaneously to pneumological centers participating in the study, the corresponding economic outcomes being assessed at baseline and after a 1-year survey. A total of 748 COPD patients were enrolled, of whom 561 [408 m, mean age 70.3 years (SD 9.2)] were defined as eligible by the Steering Committee. At the baseline visit, the severity of COPD (graded according to GOLD 2001 guidelines) was 24.2% mild COPD, 53.7% moderate and 16.8% severe. In the 12 months prior to enrollment, 63.8% visited a general practitioner (GP); 76.8% also consulted a national health service (NHS) specialist; 22.3% utilized Emergency Care and 33% were admitted to hospital, with a total of 5703 work days lost. At the end of the 1-year survey, the severity of COPD changed as follows: 27.5% mild COPD, 47.4% moderate and 19.4% severe. Requirement of health services dropped significantly: 57.4% visited the GP; 58.3% consulted an NHS specialist; 12.5% used Emergency Care and 18.4% were hospitalized. Compared to baseline, the mean total cost per patient decreased by 21.7% (p<0.002). In conclusion, a significant reduction in the use of health resources and thus of COPD-related costs (both direct and indirect costs) was observed during the study, likely due to a more appropriate care and management of COPD patients.

Entities:  

Mesh:

Year:  2007        PMID: 17881206     DOI: 10.1016/j.rmed.2007.08.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  22 in total

1.  Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy.

Authors:  O Zaniolo; S Iannazzo; L Pradelli; M Miravitlles
Journal:  Eur J Health Econ       Date:  2010-11-18

2.  Poor adherence to guidelines for long-term oxygen therapy (LTOT) in two Italian university hospitals.

Authors:  Alessia Verduri; Licia Ballerin; Marzia Simoni; Marcello Cellini; Emidia Vagnoni; Pietro Roversi; Alberto Papi; Enrico Clini; Leonardo M Fabbri; Alfredo Potena
Journal:  Intern Emerg Med       Date:  2013-01-18       Impact factor: 3.397

3.  Adherence of Elderly Patients with Cardiovascular Disease to Statins and the Risk of Exacerbation of Chronic Obstructive Pulmonary Disease: Evidence from an Italian Real-World Investigation.

Authors:  Federico Rea; Giulia Calusi; Matteo Franchi; Davide Liborio Vetrano; Giuseppe Roberto; Stefano Bonassi; Ursula Kirchmayer; Alessandro Chinellato; Alessandra Bettiol; Janet Sultana; Alessandro Mugelli; Giovanni Corrao
Journal:  Drugs Aging       Date:  2018-12       Impact factor: 3.923

4.  Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update.

Authors:  Roberto W Dal Negro; Luca Bonadiman; Paola Turco; Silvia Tognella; Sergio Iannazzo
Journal:  Clinicoecon Outcomes Res       Date:  2015-03-16

5.  AIMAR survey on COPD phenotypes.

Authors:  Maria Sandra Magnoni; Andrea Rizzi; Alberto Visconti; Claudio F Donner
Journal:  Multidiscip Respir Med       Date:  2014-03-17

Review 6.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

7.  COPD a social disease: inappropriateness and pharmaco-economics. The role of the specialist: present and future.

Authors:  Claudio F Donner; Mirco Lusuardi
Journal:  Multidiscip Respir Med       Date:  2010-12-20

Review 8.  Optimizing economic outcomes in the management of COPD.

Authors:  Roberto Dal Negro
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

9.  Prevalence of different comorbidities in COPD patients by gender and GOLD stage.

Authors:  R W Dal Negro; L Bonadiman; P Turco
Journal:  Multidiscip Respir Med       Date:  2015-08-05

10.  Sensitivity of the COPD assessment test (CAT questionnaire) investigated in a population of 681 consecutive patients referring to a lung clinic: the first Italian specific study.

Authors:  Roberto W Dal Negro; Luca Bonadiman; Paola Turco
Journal:  Multidiscip Respir Med       Date:  2014-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.